Printer Friendly

Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents.

Atherosclerosis is a complex inflammatory process that is characterized by the presence of monocytes/macrophages and T lymphocytes in the atheroma (1). Fatty streaks, the earliest detectable lesions in atherosclerosis, contain macrophage-derived foam cells that differentiate from recruited blood monocytes. In addition, more advanced atherosclerotic lesions such as fibro-fatty plaques are the result of monocyte recruitment together with smooth muscle cell migration and proliferation. Moreover, macrophage density is greater in the shoulder region of plaques that rupture. Monocytes/macrophages are pivotal in atherosclerosis and are present at all stages of atherosclerosis, from nascent fatty streak lesions to culmination in acute coronary syndromes (2).

Macrophages promote atherosclerosis via production of various key biomediators (3), including cytokines such as interleukin (IL)-[beta], [1] tumor necrosis factor-[alpha] (TNF-[alpha]), and IL-6; chemokines such as IL-8 and monocyte chemoattractant protein-1 (MCP-1); matrix metalloproteinases; and integrins (CD11b and VLA4). Although concentrations of the cytokines IL-1, IL-6, and TNF-[alpha] are increased in patients with increased risk of atherosclerosis (3-5), monocytic concentrations of these cytokines appear to be a more sensitive indicator of inflammatory status (6). Importantly, monocytic function has been reported to be altered in patients with increased cardiovascular risk, including dyslipidemia, diabetes, smoking, and endstage renal disease (7-9).

Therapies that have been shown to reduce cardiovascular events appear to have antiinflammatory properties (10-17). This has been well documented with the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors (statins) (10-12). Newer, specific antiinflammatory therapies are also being developed; it therefore is essential to have a simple in vitro screening assay to test their antiinflammatory effects. Because inflammation is pivotal to atherosclerosis and the monocyte/macrophage is a critical participant, we developed an in vitro model system of monocytic cells to test the antiinflammatory properties of various compounds, i.e., dietary supplements and pharmacologic agents.

Materials and Methods

Human monocytic leukemia THP-1 cells were obtained from the American Type Culture Collection. The cells were maintained in endotoxin-free RPMI-1640 containing 5.5 mmol/L glucose, 50 [micro]mol/L mercaptoethanol, 100 mL/L fetal bovine serum, 2 mmol/L glutamine, 1 mmol/L sodium pyruvate, and 10 mmol/L HEPES and were used for experiments between the third and fifth passages. The various cytokine ELISAs used were obtained from R&D systems. N-Acetylcysteine (NAC), vitamin E [[alpha]-tocopherol (AT)], catechin, epigallocatechin gallate (EGCG), ciglitazone, and lovastatin were obtained from Sigma Chemical Company. Candesartan was obtained from AstraZeneca (Wilmington, DE) as a kind gift. All of these compounds were dissolved in either dimethyl sulfoxide or ethanol. The concentration of vehicle control never exceeded 1 mL/L in culture medium. A vehicle control was run in all experiments. Cell viability, as assessed by the 3-(4,5-dimethylthiazol-z-yl)-2,5, diphenyl tetrazolium bromide assay, was >95% in all experiments.


The human monocytic leukemia cell line THP-1 was chosen for this study because it is a highly differentiated monocytic cell line with phagocytic properties and has Fc as well as Cab receptors. Indeed, it is the most commonly used model to study the biology of foam cell formation because it can be easily induced to a macrophage phenotype after phorbol ester treatment (18). Furthermore, these cells have been reported to produce proinflammatory cytokines (IL-1, IL-6, and TNF) and chemokines (IL-8 and MCP-1) in response to lipopolysaccharide (LPS) stimulation (19, 20). The THP-1 cell line rather than human monocytes was used in this in vitro model system to minimize variability and to allow for high throughput. Using the THP-1 cells, we have demonstrated that under hyperglycemic conditions, superoxide anion and IL-6 release are increased, as observed in diabetic monocytes, and have elucidated the molecular mechanisms that mediate the increased superoxide anion and cytokine release from diabetic monocytes (21-23). Thus, like other investigators, we have found that the THP-1 cell line is the best in vitro model system to understand monocyte/macrophage biology as it relates to human disease.

The cells were grown in 75-[mm.sup.2] flasks in RPMI supplemented with fetal bovine serum until they attained 70% confluency. On reaching confluency, the cells were plated in 12-well tissue culture plates (~5 x [10.sup.5] cells/mL) in serum-free medium at 37[degrees]C in 5% C[O.sub.2]. The cells were challenged with different concentrations (0-1000 [micro]g/L) of LPS for different times (4,12, and 24 h). The supernatants were harvested after each time point and stored frozen at -20[degrees]C until analysis. IL-1[beta], TNF-[alpha], and IL-6 were quantified in all supernatants. The cells were lysed in 0.1 mol/L NaOH. The results for release of each cytokine are reported as per milligram of protein. The intra- and interassay CVs for the cytokine assays were <10%. The specific time points at which maximum cytokine stimulation was achieved were noted.


The various compounds selected were divided into 2 categories: dietary supplements and pharmacologic agents. From our preliminary experiments, we found that TNF-[alpha] was the cytokine released at the earliest time point (4 h as opposed to 24 h for IL-1[beta] and IL-6) and also at the lowest LPS concentration (half maximum ~50 [micro]g/L) as discussed in Results. Therefore, for all of our future experiments testing the antiinflammatory effects of these compounds, THP-1 cells were incubated with LPS (50 [micro]g/L) for a duration of 4 h and TNF-[alpha] concentrations were assayed in supernatants. THP-1 cells were pretreated with different concentrations of various compounds at biologically relevant concentrations. After 1 h of pretreatment with these compounds, the cells were challenged with LPS (50 [micro]g/L) for 4 h. The supernatants were used for measurement of TNF-[alpha]. The range of TNF-[alpha] calibrators was 0-1000 ng/L.


All experiments were repeated at least 3 times. The Student unpaired t-test was used to compute the differences, with significance set at 5%. ANOVA was used to assess dose-response effects.



THP-1 cells revealed maximum stimulation of TNF-[alpha] at an LPS concentration of 100 [micro]g/L after a 4-h incubation (Fig. 1); however, both IL-1[beta] and IL-6 continued to increase with maximum release after 24 h at the highest LPS concentration ([greater than or equal to] 500 [micro]g/L; Fig. 2). Whereas LPS induced the release of all 3 cytokines, TNF-[alpha] secretion was maximum at the lowest LPS concentration and shortest duration of incubation. The calculated half-maximum dose of LPS required for TNF-[alpha] secretion at 4 h was 50 [micro]g/L. Thus, all further experiments used TNF-[alpha] as an endpoint with incubation for 4 h at an LPS concentration of 50 [micro]g/L.


THP-1 cells were pretreated for 1 h with various compounds or vehicle control. The results for TNF-[alpha] release from THP-1 cells pretreated with various dietary supplements, AT (25, 50, and 100 [micro]mol/L), catechin (0.25, 0.5, and 1 [micro]mol/L), and EGCG (10-50 [micro]mol/L) are shown in Table 1. The results revealed that AT inhibited TNF-[alpha] release significantly at all concentrations used in the study: 45%, 57%, and 62% inhibition at 25, 50, and 100 [micro]mol/L AT, respectively. EGCG also dose-dependently inhibited TNF-[alpha] secretion (47%, 52%, and 65% inhibition at 10, 25, and 50 [micro]mol/L EGCG, respectively). However, for NAC, TNF-[alpha] secretion was significantly inhibited only at concentrations [greater than or equal to] 3 mmol/L ([greater than or equal to] 28% inhibition), and for catechin, TNF-[alpha] secretion was significantly inhibited only at concentrations [greater than or equal to] 0.5 [micro]mol/L ([greater than or equal to] 42% inhibition).




The results for LPS-stimulated TNF-[alpha] release from THP-1 cells pretreated with various pharmacologic agents are shown in Table 2. All 3 drugs--lovastatin, ciglitazone, and candesartan--caused significant inhibition of TNF-[alpha] release. Lovastatin (a well-known HMG-CoA reductase inhibitor with pleiotropic effects) significantly inhibited TNF-[alpha] release at concentrations [greater than or equal to] 1 [micro]mol/L (43% and 49% inhibition at 1 and 5 [micro]mol/L, respectively; P <0.05). For ciglitazone, doses [greater than or equal to] 2.5 [micro]mol/L significantly inhibited TNF-[alpha] release (31% and 43% inhibition at 2.5 and 5 [micro]mol/L, respectively; P <0.05). Candesartan [an angiotensin receptor type I blocker (ARB)] at concentrations [greater than or equal to] 1.0 [micro]mol/L significantly inhibited TNF-[alpha] release (45% and 49% at 1 and 5 [micro]mol/L, respectively; P <0.05).


Inflammatory processes are recognized to play a central role in the pathogenesis of atherosclerosis and its complications. The monocyte/macrophage is a crucial cell in atherosclerosis and is present in all stages of atherosclerosis. The importance of monocytes/macrophages in atherosclerosis is underscored by knock-out studies, which showed that loss of MCP-1 or its cognate receptors leads to a decrease in atherosclerosis. Monocytes/macrophages secrete the proinflammatory cytokines IL-1, IL-6, and TNF-[alpha]. The plasma concentrations of several markers of inflammation have been found to be associated with future cardiovascular risk in a variety of clinical settings (4, 5, 9). The plasma half-life of cytokines is relatively short, and the monocytic release of cytokines is a more sensitive and reliable indicator of inflammatory status (3).

Thus, considering the critical role of monocytes/macrophages in the inflammatory process and atherosclerosis, we developed an in vitro cell-based system using THP-1 cells after LPS stimulation to test the antiinflammatory effects of different compounds. The rationale for using LPS as the chosen agonist is based on recent data suggesting that the LPS receptors (toll-like receptor-4) are pathogenically related to atherosclerosis (24). Such a model system depicted increased secretion of IL-1, IL-6, and TNF-[alpha] after LPS stimulation. It is pertinent here to state that all of these inflammatory cytokines are reported to be increased in atherosclerotic lesions (3). In the current study, our aim was to develop a rapid, high-throughput assay as a first-line in vitro screen to provide a cost-effective strategy to test novel antiinflammatory compounds. We therefore focused only on TNF-[alpha] secretion because secretion reached maximum at the lowest concentration of LPS and at the shortest duration of incubation.

Dietary micronutrients such as AT and flavonoids have been shown to have, in addition to their antioxidant activity, antiinflammatory properties. In this system, we tested the effects of AT, catechin, EGCG, and NAC, a potent provider of sulfhydryl groups and an inhibitor of nuclear factor-[kappa]B. Catechins are flavonoid compounds that appear predominantly in green tea. Smaller amounts of catechins are also present in black tea, grapes, wine, and chocolate. The polyphenol catechins in green tea include gallocatechin, epigallocatechin, epicatechin, and EGCG. In experimental models, catechins showed a wide range of protective effects, including cardioprotective and chemoprotective properties, particularly, the tea catechin EGCG (25, 26). Furthermore, high-dose AT supplementation has been shown previously to have antiinflammatory effects (27) in diabetic patients.

In preventive cardiology, one of the major breakthroughs has been the reduction in cardiovascular events as a result of the introduction of HMG-CoA reductase inhibitors (10-12), commonly known as statins. The reduction in cardiovascular endpoints with statin use could be partly ascribed to their antiinflammatory effects (27). Numerous studies have shown that statins lower C-reactive protein (CRP) (10-12), TNF-[alpha], IL-1, IL-6, IL-8, and MCP-1 concentrations (10). In this study, we used lovastatin, which in the AFCAPS-TEXCAPS study was shown to reduce the number of cardiovascular events and lower CRP concentrations (12). We show that in our in vitro model system, lovastatin significantly inhibited LPS-stimulated TNF-[alpha] release.

The peroxisome proliferator-activated receptor-[gamma] (PPAR-[gamma]) agonists, as a class of drugs, improve insulin sensitivity and also have antiinflammatory properties (13,14). This class of drugs has revolutionized the treatment of diabetes. They have been shown to up-regulate adiponectin. Numerous investigators have shown that PPAR-[gamma] agonists decrease CRP (28, 29) and plasma MCP-1, TNF, and serum amyloid A (29) concentrations after therapy. In addition, it has been reported that PPAR-[gamma] has pleiotropic functions, exhibiting immunomodulatory activity in obesity as well as type 2 diabetes (13). We therefore tested the effect of ciglitazone, a PPAR-[gamma] agonist, in our model system. Ciglitazone significantly inhibited LPS-induced TNF-[alpha] release. The reduction in TNF-[alpha] in our model system could be a mechanism explaining the reduction in insulin resistance because TNF-[alpha] impairs insulin signaling (30).

Drugs that inhibit the renin-angiotensin system, such as angiotensin-converting enzyme inhibitors and ARBs, are also are known to modulate the processes of inflammation and possibly the atherosclerotic process (15, 16, 31, 32). Importantly, candesartan has also been shown to exhibit pleiotropic effects by significantly lowering plasma TNF-[alpha] concentrations in hypertensive patients (31). In our in vitro model system, candesartan (an ARB) significantly inhibited LPS-stimulated TNF-[alpha] release, confirming these in vivo findings.

Thus, the findings in this study clearly demonstrate that our in vitro model system is suitable for testing antiinflammatory effects because the dietary supplements (21, 33, 34) and pharmacologic agents (13,16,17, 28, 31) tested in this study have been shown to display antiinflammatory properties after chronic intake in patients/ volunteers. Importantly, TNF-[alpha] release has been implicated in cardiovascular-related diseases (30).

In conclusion, based on our results, we propose that the model system (LPS-stimulated monocytic release of TNF-[alpha]) is a rapid in vitro screening assay suitable for direct testing of compounds for antiinflammatory effects. If a compound shows antiinflammatory effects in this in vitro cell-based assay, testing should be followed by studies in relevant animal models and in human volunteers, focusing on various aspects of the inflammatory cascade (soluble cell adhesion molecules, cytokines, and chemokines, as well as downstream proteins such as serum amyloid A and CRP).

This work was supported by National Institutes of Health Grant NIH K24 AT00596 and an Edmondson fellowship (to J.T.) from UC Davis.

Received June 14, 2005; accepted August 18, 2005.

Previously published online at DOI: 10.1373/clinchem.2005.056093


(1.) Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.

(2.) Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis [Review]. Circulation 2002;105:1135-43.

(3.) Devaraj S, Harris A, Jialal I. Modulation of monocyte-macrophage function with [alpha]-tocopherol: implications for atherosclerosis [Review]. Nutr Rev 2002;60:8-14.

(4.) Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-[alpha] and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101:2149-53.

(5.) Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.

(6.) Wirtz PH, von Kanel R, Rohleder N, Fischer JE. Monocyte proinflammatory cytokine release is higher and glucocorticoid sensitivity is lower in middle aged men than in women independent of cardiovascular risk factors. Heart 2004;90:853-8.

(7.) Jialal I, Devaraj S. Oxidative stress, inflammation, and diabetic vasculopathies: the role of a tocopherol therapy [Review]. Free Radio Res 2002;36:1331-6.

(8.) van Tits U, Demacker PN, de Graff J, Hak-Lemmers HL, Stalenhoef AF. [alpha]-Tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals. Am J Clin Nutr 2000;71:458-64.

(9.) Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease [Review]. Curr Drug Targets Inflamm Allergy 2003;2:257-65.

(10.) Aster E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004;177:161-6.

(11.) Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001;103:1933-5.

(12.) Ridker PM, Rifai N, Cleartield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.

(13.) Staels B. PPARy and atherosclerosis. Curr Med Res Opin 2005; 21: S13-20.

(14.) Castrillo A, Tontonoz P. PPARs in atherosclerosis: the clot thickens [Review]. J Clin Invest 2004;114:1538-40.

(15.) Khan BV, Navalkar S, Khan QA, Rahman ST, Parthasarathy S. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 2001;38:1662-7.

(16.) Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001;37:440-4.

(17.) Devaraj S, Li D, Jialal I. The effects of [alpha]-tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1R secretion, and monocyte adhesion to endothelium. J Clin Invest 1996;98:756-63.

(18.) Banka CL, Black AS, Dyer CA, Curtiss LK. THP-1 cells form foam cells in response to coculture with lipoproteins but not platelets. J Lipid Res 1991;32:35-43.

(19.) Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-[kappa]B. Cell Immunol 2002;220:83-95.

(20.) Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001;69:959-62.

(21.) Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of [alpha]-tocopherol supplementation. Circulation 2000;102:191-6.

(22.) Venugopal SK, Devaraj S, Yang T, Jialal I. [alpha]-Tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-[alpha]. Diabetes 2002; 51:3049-54.

(23.) Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{[alpha]} and -{[beta]}. Diabetes 2005;54:85-91.

(24.) Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103-8.

(25.) Hofmann CS, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53. FASEB J 2003;17:702-4.

(26.) Rosenkranz S, Knirel D, Dietrich H, Flesch M, Erdmann E, Bohm M. Inhibition of the PDGF receptor by red wine flavonoids provides a molecular explanation for the "French paradox". FASEB J 2002;16:1958-60.

(27.) Singh U, Jialal I. Anti-inflammatory effects of [alpha]-tocopherol. Ann N Y Acad Sci 2004;1031:195-203.

(28.) Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-84.

(29.) Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-35.

(30.) Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-[alpha]- and obesity-induced insulin resistance. Science 1996;271:665-8.

(31.) Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003;42:905-10.

(32.) Sattler KJ, Woodrum JE, Galili O, Olson M, Samee S, Meyer FB, et al. Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor-[kappa]B activation and C-reactive protein expression in human carotid artery plaques. Stroke 2005;36:14-20.

(33.) Devaraj S, Jialal I. [alpha]-Tocopherol supplementation decreases serum CRP and monocyte IL-6 levels in normal volunteers and type 2 diabetic patients. Free Radio Biol Med 2000;29:790-2.

(34.) Jialal I, Devaraj S, Kaul N. The effect of [alpha]-tocopherol on monocyte proatherogenic activity [Review]. J Nutr 2001;131:389S-94S.

[1] Nonstandard abbreviations: IL, interleukin; TNF-[alpha], tumor necrosis factor-[alpha]; MCP-1, monocyte chemoattractant protein-1; HMG-CoA, hydroxymethylglutaryl-CoA; NAC, N-acetylcysteine; AT, [alpha]-tocopherol; EGCG, epigallocatechin gallate; LPS, lipopolysaccharide; ARB, angiotensin receptor type I Mocker; CRP, C-reactive protein; and PPAR-[gamma], peroxisome proliferator-activated receptor-[gamma].


Laboratory for Atherosclerosis and Metabolic Research, Department of Pathology & Laboratory Medicine, University of California, Davis Medical Center, Sacramento, CA.

* Address correspondence to this author at: Laboratory for Atherosclerosis and Metabolic Research, Department of Pathology & Laboratory Medicine, University of California, Davis Medical Center, 4635 IInd Ave., Res Bldg. 1, Rm 3000, Sacramento, CA 95817. Fax 916-734-6593; e-mail
Table 1. Effects of various dietary supplements on TNF-[alpha]
secretion in LPS-stimulated THP1 cells. (a)

Treatment TNF-[alpha] secretion,
 pg/mg of protein

Control 82 (38)
LPS (50 [micro]g/L) 4772 (875) (b)
LPS + 25 [micro]mol/L AT 2668 (465) (c)
LPS + 50 [micro]mol/L AT 2057 (622) (c)
LPS + 100 [micro]mol/L AT 1844 (331) (d)
LPS + 0.25 [micro]mol/L catechin 3243 (894)
LPS + 0.5 [micro]mol/L catechin 2736 (734) (e)
LPS + 1.0 [micro]mol/L catechin 2026 (423) (c)
LPS + 10 [micro]mol/L EGCG 2515 (469) (c)
LPS + 25 [micro]mol/L EGCG 2296 (731) (c)
LPS + 50 [micro]mol/L EGCG 1655 (336) (d)
LPS + 1 mmol/L NAC 3725 (923)
LPS + 3 mmol/L NAC 2979 (835) (e)
LPS + 6 mmol/L NAC 1264 (125) (c)

(a) The results are the mean (SD) of 3 different experiments run in

(b) P <0.001, compared with control.

(c-e) Compared with LPS stimulation alone:

(c) P <0.01;

(d) P <0.001;

(e) P <0.05.

Table 2. Effects of various therapeutic drugs on TNF-[alpha] secretion
in LPS-stimulated THP1 cells. (a)

Treatment TNF-[alpha] secretion, pg/mg of

Control 69 (29)
LPS (50 [micro]g/L) 4310 (1409) (b)
LPS + 0.5 [micro]mol/L ciglitazone 4208 (1085)
LPS + 1.0 [micro]mol/L ciglitazone 3578 (670)
LPS + 2.5 [micro]mol/L ciglitazone 2973 (271) (c)
LPS + 5.0 [micro]mol/L ciglitazone 2476 (429) (c)
LPS + 0.5 [micro]mol/L lovastatin 3349 (803)
LPS + 1.0 [micro]mol/L lovastatin 2497 (350) (c)
LPS + 5.0 [micro]mol/L lovastatin 2211 (64) (c)
LPS + 0.5 [micro]mol/L candesartan 2880 (741)
LPS + 1.0 [micro]mol/L candesartan 2372 (514) (c)
LPS + 5.0 [micro]mol/L candesartan 2228 (464) (c)

(a) The results are the mean (SD) of 3 different experiments run in

(b) P <0.001 compared with control.

(c) P <0.05 compared with LPS stimulation alone.
COPYRIGHT 2005 American Association for Clinical Chemistry, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Lipids, Lipoproteins, and Cardiovascular Risk Factors
Author:Singh, Uma; Tabibian, James; Venugopal, Senthil K.; Devaraj, Sridevi; Jialal, Ishwarlal
Publication:Clinical Chemistry
Date:Dec 1, 2005
Previous Article:Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with...
Next Article:Comparison of the relationships between serum apolipoprotein B and serum lipid distributions.

Related Articles
Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density...
Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences.
An unusual case of severe hypertriglyceridemia and splenomegaly.
In vitro testing for anti-inflammatory properties of compounds.
Cut points for lipids and lipoproteins in children and adolescents: should they be reassessed?
Laboratory assessment of HDL heterogeneity and function.
Vitamin E and coronary heart disease in Tunisians.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters